The pharmacokinetics are fundamentally different, and those differences drive every dosing decision you will make
Estrogen is synthesized in the following tissues:[ref] ovaries (major source in women, E2) testes (males) fat cells (E1, especially post-menopause) brain liver pancreas intestines adrenals The precursor for estrogen is cholesterol, which is first converted (using CYP11A1) into progesterone, which is then converted (using CYP17A1) into androstenedione
All indexes of the pilot-scale test samples and the three verification samples in the detection batch are in accordance with the drawn draft of the quality standard of the injection reduced glutathione, and the number, the position, the single impurity content and the total impurity content of the impurities of the samples in several batches are basically consistent, which indicates that the difference between the batches of the samples is small
These are not abstract policy discussions
[DOI] [PMC free article] [PubMed] [Google Scholar] 277.Adedara IA, Ajayi BO, Awogbindin IO, Farombi EO
